Discovery & history

• What thymosin beta-4 is and how TB-500 relates to it
• The actin-sequestration mechanism behind its repair reputation
• What the human trials actually show, tier by tier
• How to read dosing, safety, and the cancer question critically

1. 01 Discovery & history From a thymus extract to the cell’s actin manager free
2. 02 The molecule and its structure A floppy 43-residue chain that grips actin paid
3. 03 Actin biology, the core mechanism The actin bank that powers cell movement paid
4. 04 Cell migration & angiogenesis From actin reserve to cells that move and vessels that grow paid
5. 05 Wound healing The flagship use, and its honest evidence paid
6. 06 Anti-inflammatory & remodeling Calming inflammation without shutting it off paid
7. 07 Cardiac & neurological repair The boldest claims, and the honest contradictions paid
8. 08 Clinical trials & human evidence What the actual human studies show paid
9. 09 Dosing & Administration How TB-500 is prepared and discussed, for education only paid
10. 10 Safety & Side Effects What we know, what we do not, and the cancer question paid
11. 11 Regulatory status & anti-doping Sold as a research chemical, not approved, and banned in sport paid
12. 12 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

The story starts in 1966, when Allan Goldstein and Abraham White published on a partially purified thymic factor they called "thymosin". The record of that paper in this course’s research base is a landing page carrying only its title, which describes a thymic lymphocytopoietic factor, so the tissue it came from and the hopes attached to it are not things this course states. Thymosin beta-4 itself was sequenced from calf thymus, in its bovine form, in 1981. The name stuck even after later work found it in many rat and mouse tissues, including in mice born without a thymus, so it does not come only from the thymus.

That reframing matters for how you read every claim that follows. A molecule the body keeps in almost every cell is doing fundamental cytoskeleton work, which is very different from a targeted drug. It also raises the central puzzle of the whole field: if levels are already high inside cells, what does injecting more actually add?

The timeline below tracks the shift from immunology to actin biology, and the next pages follow it into human trials. Notice how long the basic science ran before any trial started, and that the phase 3 trials that were completed tested an eye drop, not the injuries most people associate with TB-500.

Reading this honestly, the science is genuinely deep and old, but the translation to approved human therapy is still incomplete after fifty years. The strongest clinical signals are recent and narrow. That tension, real biology against thin clinical proof, is the throughline of this course.

Stripped of marketing, thymosin beta-4 is a short, floppy chain of 43 amino acids with an acetylated start, mostly unstructured until it binds actin. Its job is to bind single actin molecules one to one and hold them back from building filaments. The numbers below describe that full protein. The TB-500 material identified in the analytical literature is a 7-residue slice of it (Ac-LKKTETQ, which the FDA gives as 889.01 g/mol), so read the two sets of numbers separately. A few key terms anchor everything else in the course.

Those numbers describe the full protein; they do not settle how either molecule should be given. As the panel below sets out, every route documented for either molecule in this course’s research base is an injection or a topical application, an eye drop or a wound gel, and no source here tests swallowing one. The lack of a rigid structure is covered in the next unit, which describes the chain as mostly unstructured until it binds actin.

Thymosin beta-4 belongs to a small family of actin-binding peptides, and seeing it as one of a family rather than a unique miracle molecule is useful. The family framing is also where courses overreach, so here is what this course’s research base actually supports: beta-thymosins are described as binding monomeric actin one to one and acting as buffers, and the element quoted as present in all beta-thymosin/WH2 domains is an amphipathic N-terminal alpha helix. The LKKTET motif, a six-residue segment the FDA review describes as the actin-binding region of thymosin beta-4, is described for thymosin beta-4 itself; no source here establishes it as a family-wide anchor.

The family framing also flags a caution that returns in the safety unit. Reviews of the family note that increased beta-thymosin expression might promote metastasis, possibly by making cells more mobile, and describe these peptides as involved in tumor metastasis as well as normal cell migration. A cell-movement tool can serve healing and, in the wrong context, cells you do not want moving.

Before the mechanisms, the honest picture: what is genuinely supported versus what is hopeful extrapolation. Thymosin beta-4 is unusual among gray-market peptides because it has real human trials: RegeneRx sponsored trials in chronic wounds, and ReGenTree sponsored two completed phase 3 trials of an eye drop in dry eye, with 601 and 700 participants. The problem is not that the trials never happened. It is that of the phase 3 trials in this course’s research base that have reported, the two completed dry-eye trials and a smaller corneal-disease trial that was stopped early, none showed a clear benefit on its primary endpoint: the two dry-eye trials posted no advantage over placebo, and the smaller trial narrowly missed significance.

Hold those tiers apart and most of the online noise resolves. The molecule is real and its biology is solid, the eye and wound programs reached genuine large human trials, and the tendon-and-ligament use that drives most demand sits on the weakest evidence of all. Keeping that ladder straight is the single most useful skill this course teaches.

A few specific claims you will meet online, held against the evidence ladder above. The pattern is rarely "false", it is "real effect in animals or cells, rounded up into a human promise".

Notice the pattern in those four verdicts: the claims with real human trials behind them, the eye and the heart, still came back negative or mixed, and the tendon-and-ligament claim has no trial at all in this course’s research base. Calibrating each claim this way, rather than rounding everything up or down, is exactly what an honest course should surface.